Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer.
Robert Hugh JonesKarim FizaziNicholas D JamesTeuvo L TammelaNobuaki MatsubaraFrank PriouPhilippe BeuzebocThierry LesimplePetri BonoVesa KatajaJorge A GarciaAndrew S ProtheroeNeal D ShoreJohn AspegrenHeikki JoensuuIris KussSabine Fiala-BuskiesEgils VjatersPublished in: Prostate cancer and prostatic diseases (2023)
Long-term darolutamide treatment was well tolerated; no new safety signals observed. In patients with mCRPC, long-term darolutamide treatment was well tolerated and no new safety signals were observed. These findings are consistent with previous reports, demonstrating a favorable safety and tolerability profile of darolutamide.